News und Analysen
UnitedHealth Group: Pariah to Pole Position to Buy the Dip Levels
UnitedHealth Group Inc. (NYSE: UNH) is a bellwether for the health insurance industry. The company symbolized the flaws in managed care organizations
BioNTech veröffentlicht am 5. Mai 2025 Ergebnisse für das erste Quartal 2025 und informiert über operativen Fortschritt
MAINZ, Deutschland, 22. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. Mai 2025, die Ergebnisse für das erste Quartal 2025
Unitedhealth Stock: Dramatic 20% Plunge Shocks Market
UnitedHealth Group shares experienced a catastrophic drop on Thursday, plummeting by over 20% following disappointing first-quarter results. The healthcare giant saw its stock trading as low as
Tariff-Resistant Abbott Laboratories on Track for New Highs
Abbott Laboratories (NYSE: ABT) is not immune to the impact of tariffs on its medical device business. However, the company’s diversified business is tariff-resistant, and moves are being made to
Viking Therapeutics Stock Pops But Struggles to Hold Gains
Viking Therapeutics Inc. (NASDAQ: VKTX) has taken investors on a wild ride since the beginning of 2024. At one point, VKTX stock was up 375% from its
Johnson & Johnson Earnings Were More Good Than Bad—Time to Buy?
Johnson & Johnson (NYSE: JNJ) delivered a solid earnings report on April 15.
[content-module:CompanyOverview|NYSE:JNJ]On the one hand, the company beat on the top and bottom lines and offered
2 Healthcare Recession-Resistant Stocks Unaffected by Tariffs
The medical sector stocks, notably the health insurance carriers, took a major drubbing in 2024 as Medicare Advantage (MA) plans continued to drive higher utilization costs, eating away at
Amgen Stock: Sandoz Lawsuit Threatens Blockbuster Drug Revenue
The Swiss generics specialist Sandoz has filed an antitrust lawsuit against Amgen, challenging what it describes as illegal tactics to block competition for Enbrel, Amgen's blockbuster medication
5 Winning Plays Outperforming the S&P This Year
While macroeconomic headwinds, tariffs, inflation, interest rates, and fears of a recession impact the broad market S&P 500, not all stocks are in the same position.
This is a look at five stocks
Verkauf bei Stärke in der Pharmaindustrie, rät Mizuho's Jared Holz
Vertex baut sein Chief Strategy Office aus, um e-Invoicing und globale Compliance-Initiativen voranzutreiben
Zwei führende Branchenexperten schließen sich dem Chief Strategy Office von Vertex an. Ziel ist es, Produktinnovationen und globale Compliance-Strategien für Kunden zu stärken.
KING OF PRUSSIA, Pa
3 Biopharmaceutical Stocks Bucking the Sell-Off
With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be
Die Auswirkungen von Zöllen auf Pharma-Aktien: Eine eingehende Analyse
Eli Lilly Stock: Trump's Tariff Threat Impacts Outlook
Eli Lilly shares could face pressure after Donald Trump reinforced his intention to impose tariffs on imported pharmaceuticals. The Republican president plans to implement duties of "25% or higher"
Der Black Friday kommt früh – mit der Sommer-Sonderaktion von Blue Diamond Resorts
ST. MICHAEL, Barbados, April 09, 2025 (GLOBE NEWSWIRE) -- Nach der überwältigenden Resonanz auf sein jüngstes Angebot legt Blue Diamond Resorts mit der Einführung seiner „Summer Black
Who Led Buybacks to End 2024? Hint: It Wasn’t Big Tech
Big tech has become known for its big-time use of buybacks. In the last quarter of 2024, Apple (NASDAQ: AAPL), Alphabet (NASDAQ: GOOG), Meta Platforms (NASDAQ: META), and Microsoft (NASDAQ: MSFT)
Can Solid Biosciences Challenge Sarepta in the DMD Market?
When it comes to treating Duchenne muscular dystrophy (DMD), big news recently surfaced. DMD is a muscle disease. It usually first shows up in boys aged two to five years. Genetic alterations
Johnson & Johnson Stock: Acquisition Progress Amid Talc Setback
Johnson & Johnson is advancing toward completing its strategic acquisition of Intra-Cellular Therapies, expected to finalize around April 2, 2025, following shareholder approval on March 27. The
Natera Stock: Executives Sell Shares Amid Strong Performance
Natera, a medical laboratory company listed on NASDAQ with a market capitalization of €19.08 billion, recently saw several of its executives selling shares. CEO Steven Leonard sold company shares
Eli Lilly Stock: Legal Battles Over Unauthorized Drug Production
Eli Lilly has intensified its legal campaign against pharmacies producing unauthorized versions of its weight-loss medication tirzepatide. The pharmaceutical giant filed lawsuits against Strive
Regeneron: Der Kampf um globale Gleichheit im Pharmasektor
2 Healthcare Stocks to Watch as JPMorgan Boosts Gilead Rating
When Wall Street analysts decide to come out of their caves and boost a certain stock, retail investors should pay attention to the motives behind the decision as it can signal a shift in
Johnson & Johnson Stock: Court Setback Triggers Financial Shift
Johnson & Johnson (J&J) faces a significant legal defeat as a US bankruptcy court in Texas rejected its subsidiary Red River Talc LLC's proposed settlement plan. This plan, valued at approximately
Rückschlag für Impfstoffaktien nach Rücktritt bei der FDA
Zimmer Biomet Stock: Dividend Payout Set for March 2025
Zimmer Biomet Holdings, a leading medical technology manufacturer specializing in orthopedics, has announced a dividend distribution of $0.24 per share scheduled for late March 2025. This payment